Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.200
0.00 (0.01%)
Nov 21, 2024, 1:05 PM EST - Market open
Plus Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Plus Therapeutics stock have an average target of 14, with a low estimate of 8.00 and a high estimate of 20. The average target predicts an increase of 1,066.57% from the current stock price of 1.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PSTV stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +566.61% | Nov 15, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $20 | Strong Buy | Maintains | $21 → $20 | +1,566.53% | Sep 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +566.61% | Aug 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +566.61% | Aug 15, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +566.61% | Aug 14, 2023 |
Financial Forecast
Revenue This Year
5.46M
from 4.91M
Increased by 11.13%
Revenue Next Year
5.10M
from 5.46M
Decreased by -6.59%
EPS This Year
-2.27
from -4.24
EPS Next Year
-2.10
from -2.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.9M | 6.7M | n/a | ||
| Avg | 5.5M | 5.1M | n/a | ||
| Low | 2.9M | 3.5M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 41.1% | 23.1% | - | ||
| Avg | 11.1% | -6.6% | - | ||
| Low | -41.0% | -35.4% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.10 | -1.42 | -1.24 | ||
| Avg | -2.27 | -2.10 | -2.54 | ||
| Low | -2.38 | -3.49 | -3.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.